Experimental recombinant hepatitis B vaccine — Competitive Intelligence Brief

Experimental recombinant hepatitis B vaccine (Experimental recombinant hepatitis B vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Immunology.

phase 3 Vaccine Hepatitis B surface antigen (HBsAg) Immunology Biologic

Target snapshot

Experimental recombinant hepatitis B vaccine (Experimental recombinant hepatitis B vaccine) — Jiangsu Province Centers for Disease Control and Prevention. This recombinant hepatitis B vaccine stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus surface antigen, providing protection against hepatitis B infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Experimental recombinant hepatitis B vaccine TARGET	Experimental recombinant hepatitis B vaccine	Jiangsu Province Centers for Disease Control and Prevention	phase 3	Vaccine	Hepatitis B surface antigen (HBsAg)
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Standard IIV4	Standard IIV4	Marshfield Clinic Research Foundation	marketed	Inactivated influenza vaccine
Varicella Virus Vaccine Live	Varicella Virus Vaccine Live	Sanofi Pasteur, a Sanofi Company	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
Streptococcus pneumoniae serotype 3	Streptococcus pneumoniae serotype 3	University of Oxford	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae serotype 3 capsular polysaccharide
Reinforced vaccination schedule	Reinforced vaccination schedule	Universidade Federal de Goias	marketed	vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
3. Pfizer · 6 drugs in this class
4. International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
5. Henogen · 3 drugs in this class
6. Pfizer Inc. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
9. BioNTech · 2 drugs in this class
10. Merck Sharp & Dohme LLC · 2 drugs in this class